ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

439
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
10 Jul 2021 05:59

Asia Shorts: Kuaishou, JD, Geely, Alibaba, Shimizu, Kubota, ASICS, SK Inno, Hynix, Doosan, Yang Ming

The Insight looks at large short interest movements across HK, Japan, Korea and Taiwan stocks and highlights large increases/decreases in shorts to...

Logo
309 Views
Share
06 Jul 2021 09:05

Pre-IPO Novotech Holdings - The Future Would Not Be Easy

This article analyzed Novotech in terms of the industry characteristics, comparison with peers (revenue growth rate, margins, etc.), the concerns...

Logo
579 Views
Share
29 Jun 2021 09:32

EM Underweight Hits Record High Among Global Managers

Active Global managers are running record underweights in Emerging Market stocks.  The average Emerging Markets allocation sits underweight -4.56%...

Logo
173 Views
Share
28 Jun 2021 10:11

Hong Kong Connect Flows: $1.2bn Outflow from Tencent

We highlight southbound inflows of Hong Kong Connect into Geely Auto (175 HK), and Wuxi Biologics (2269 HK), as well as outflows from Tencent (700...

Logo
178 Views
Share
26 Jun 2021 22:06

Global Emerging Markets Weekly: 25 June 2021

This insight provides a summary of the key news developments impacting the largest countries and constituents of the Global Emerging Markets equity...

Logo
172 Views
Share
x